Featured Research

from universities, journals, and other organizations

NIAID Launches Malaria Vaccine Trial In Africa

Date:
September 11, 2003
Source:
NIH/National Institute Of Allergy And Infectious Diseases
Summary:
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, has reached a milestone in its efforts to support accelerated development of malaria vaccines. Working with an international group of public and private partners, NIAID has launched its first trial of a candidate malaria vaccine in a country where malaria is endemic.

The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, has reached a milestone in its efforts to support accelerated development of malaria vaccines. Working with an international group of public and private partners, NIAID has launched its first trial of a candidate malaria vaccine in a country where malaria is endemic. The Phase I trial, taking place in Mali, seeks to confirm the safety and immunogenicity in adults of a candidate vaccine called FMP-1.

A key component of the NIAID Plan for Research for Malaria Vaccine Development has been to establish, in malaria-endemic areas, research centers that can support the complex clinical development of malaria vaccines. Conducting a malaria vaccine trial in Africa is important because more than 90 percent of malaria deaths occur in Africa, and the great majority of these deaths are in young children. Each year, malaria infects an estimated 300 to 500 million people worldwide and causes more than 1 million deaths, according to the World Health Organization.

This trial, the first to be conducted by Malian researchers from the Malaria Research and Training Center in the Department of Epidemiology of Parasitic Diseases at the Medical School of the University of Bamako, is taking place in Bandiagara, Mali, with NIAID support. It reflects the result of many years of effort by a group of organizations dedicated to creating an effective malaria vaccine. In addition to NIAID and the University of Bamako, the collaborators include the University of Maryland at Baltimore; NIAID's Malaria Vaccine Development Unit; the Malian Ministries of Health and Education; the Walter Reed Army Institute of Research (WRAIR); GlaxoSmithKline Biologicals (GSK); the U.S. Agency for International Development (USAID); and the World Health Organization (WHO).

Developed by WRAIR in collaboration with GSK Biologicals, and with support from USAID, the FMP-1 vaccine has already proved safe and immunogenic in two small Phase I and Phase IIa studies in the United States and an additional Phase I study in Kenya. The vaccine contains an experimental adjuvant called AS02A developed by GSK and intended to enhance the immune response.

The trial will enroll 40 adults between the ages of 18 and 55. Half of the volunteers will receive the malaria vaccine and half will serve as a control group by receiving a licensed rabies vaccine. Each volunteer will receive three injections over two months, and the researchers will follow each volunteer for one year, monitoring the long-term safety of the vaccine and analyzing the immune responses against the Plasmodium falciparum malaria parasite.


Story Source:

The above story is based on materials provided by NIH/National Institute Of Allergy And Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute Of Allergy And Infectious Diseases. "NIAID Launches Malaria Vaccine Trial In Africa." ScienceDaily. ScienceDaily, 11 September 2003. <www.sciencedaily.com/releases/2003/09/030910072410.htm>.
NIH/National Institute Of Allergy And Infectious Diseases. (2003, September 11). NIAID Launches Malaria Vaccine Trial In Africa. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2003/09/030910072410.htm
NIH/National Institute Of Allergy And Infectious Diseases. "NIAID Launches Malaria Vaccine Trial In Africa." ScienceDaily. www.sciencedaily.com/releases/2003/09/030910072410.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins